Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.6 USD | +1.54% |
|
-1.20% | -35.98% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.98% | 190M | |
+4.98% | 213B | |
+7.44% | 184B | |
+28.22% | 153B | |
+33.19% | 113B | |
+1.22% | 63.66B | |
+16.51% | 53.53B | |
+1.45% | 49.11B | |
-4.53% | 38.73B | |
+2.74% | 36.26B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Earnings Flash (NPCE) NEUROPACE Posts Q1 Revenue $14.5M, vs. Street Est of $12.2M